Use of aloe vera extract for detoxification

Abstract

The present application discloses a use of Crassocephalum rabens extract for detoxification. Since the Crassocephalum rabens extract has the activity of expelling toxic substances such as heavy metals from organisms or cells thereof, the content of heavy metals in an organism can be effectively reduced and liver function can be restored by administering an effective amount of the Crassocephalum rabens extract or a composition containing the Crassocephalum rabens extract to the organism.

Description

TECHNICAL FIELD

[0001] The present application relates to a second use of a plant extract, in particular, a use of a Crassocephalum rabens extract for detoxification. BACKGROUND

[0002] Crassocephalum rabens, also known as Crassocephalum crepidioides, is a food plant of the Asteraceae family. According to the Chinese Pharmacopoeia, the whole plant of Crassocephalum rabens has the effects of invigorating the spleen, reducing swelling, detoxifying heat, and promoting urination, and can be used to treat hypertension, cold, indigestion, headache, and mastitis. The crushed stems and leaves of Crassocephalum rabens can be used as a dressing for mosquito bites or skin injuries.

[0003] To separate the effective components from traditional Chinese herbal medicines and apply them to different products, solvent extraction is often used to separate the effective components from the Chinese herbal medicines based on the different solubilities of the effective components in different solvents. However, the separated components still have the problems of insufficient purity and residual organic extraction solvents, which may not exhibit their biological activities or may have biological toxicity. SUMMARY

[0004] The main purpose of the present application is to provide a use of a Crassocephalum rabens extract for detoxification. The Crassocephalum rabens extract disclosed in the present application has the activity of removing heavy metals from the body, and thus can effectively treat or prevent heavy metal poisoning and related diseases.

[0005] Therefore, to achieve the above purpose, the present application provides a second use of a Crassocephalum rabens extract for preparing a composition for treating or preventing heavy metal poisoning and related diseases caused by impaired organ function, and reducing blood lead concentration. That is, by administering an effective amount of the Crassocephalum rabens extract or a composition containing the Crassocephalum rabens extract to an individual, the heavy metal concentration in the body of the individual can be reduced, and the liver function of the individual can be improved, thereby achieving the effects of treating or preventing heavy metal poisoning and related diseases.

[0006] In the embodiments of the present application, the Crassocephalum rabens extract is a mixture rich in 1,2-di-O-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol (dLGG). Specifically, the Crassocephalum rabens extract is prepared from Crassocephalum rabens by an extraction process, wherein the extraction solvent used in the extraction process is water or a lower alcohol.

[0007] The lower alcohol is methanol or ethanol.

[0008] In an embodiment of the present application, the heavy metal poisoning is caused by the individual's indirect or direct contact with heavy metals, substances containing heavy metals, wherein the heavy metals are lead, zinc, cadmium, etc.

[0009] In an embodiment of the present application, the heavy metal poisoning causes the relevant organ function impairment condition to be liver function impairment, and the liver function impairment causes liver damage or liver-related diseases, and increases the content of aspartate amino transferase (AST) and alanine amino transferase (ALT) in blood.

[0010] The beneficial effects of the present application are:

[0011] The present application provides a use of Crassocephalum rabens extract for detoxification, which has the activity of removing heavy metals in the body, and thus can effectively achieve the effect of treating or / and preventing heavy metal poisoning and related diseases. BRIEF DESCRIPTION OF DRAWINGS

[0012] Figure 1A HPLC spectrum of the Crassocephalum rabens wine extract disclosed in the present application.

[0013] Figure 1B HPLC spectrum of the Crassocephalum rabens water extract disclosed in the present application.

[0014] Figure 2 HPLC spectrum of the dLGG (1,2-di-O-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol) standard.

[0015] Figure 3 Results of detecting the lead concentration in the blood of rats treated in different ways.

[0016] Figure 4 Results of detecting the AST and ALT content in the blood of rats treated in different ways. DETAILED DESCRIPTION

[0017] The present application discloses a use of Crassocephalum rabens extract for detoxification, wherein the Crassocephalum rabens extract disclosed in the present application has the activity of removing toxic substances such as heavy metals in organisms or cells thereof, and thus by administering an effective amount of Crassocephalum rabens extract or a composition containing the Crassocephalum rabens extract to an individual, the heavy metal content in the individual can be effectively reduced and liver function can be restored.

[0018] In an embodiment of the present application, the extract of Mesona Blume is a mixture rich in galactolipid (1,2-di-O-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol, dLGG) obtained by an extraction procedure of a Mesona Blume raw material. The extract of Mesona Blume of the present application can be obtained by an extraction procedure using different extraction solvents, including water, lower alcohols, carbon dioxide, etc., and extraction processes, including supercritical fluid extraction, alcohol extraction, water extraction, or a combination of any two of the above.

[0019] wherein the Mesona Blume raw material is obtained by blanching a fresh Mesona Blume.

[0020] Figure 1A and Figure 1B are the HPLC chromatograms of Mesona Blume alcohol extract and Mesona Blume water extract, respectively, wherein the Mesona Blume alcohol extract is obtained by an alcohol extraction procedure using an extraction solvent of alcohol having a concentration of 95% or more, and the Mesona Blume water extract is obtained by a water extraction procedure using water as the extraction solvent; the HPLC analysis conditions include: solvent of 98% methanol; flow rate of 1.0 mL / min; elution mode of gradient elution; injection volume of 10 μL; stop time of 60 min; column temperature of 30 °C; and detection wavelength of 210 nm.

[0021] From the results of Figure 1A and Figure 1B it can be clearly seen that there is a distinct peak at a retention time of 13.5-14.5 min, which, when compared with the HPLC chromatogram of dLGG standard (as shown in Figure 2 , can be identified as dLGG in Figure 1A and Figure 1B . Thus, it can be seen that the main indicator component in the extract of Mesona Blume obtained by any extraction process is dLGG

[0022] (1,2-di-O-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol).

[0023] In an embodiment of the present application, the extract of Mesona Blume is a mixture rich in galactolipid (1,2-di-O-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol, dLGG) obtained by an extraction procedure of a Mesona Blume raw material. The extract of Mesona Blume of the present application can be obtained by an extraction procedure using different extraction solvents, including water, lower alcohols, carbon dioxide, etc., and extraction processes, including supercritical fluid extraction, alcohol extraction, water extraction, or a combination of any two of the above.

[0024] The pre-treatment procedure is used to retain the active ingredients in the Nymphoides hydrophyllum and improve the subsequent extraction rate, and includes blanching and crushing. The blanching refers to treating fresh Nymphoides hydrophyllum with hot water or steam to obtain a Nymphoides hydrophyllum raw material. The crushing is to crush the Nymphoides hydrophyllum raw material into a powder with a size of microns using a device such as a knife or a grinder.

[0025] The extraction procedure refers to separating a Nymphoides hydrophyllum initial extract from the Nymphoides hydrophyllum powder in a low-temperature environment using water or alcohol as an extraction solvent.

[0026] The drying and concentrating procedure is used to remove or reduce the water content in the Nymphoides hydrophyllum initial extract to obtain the Nymphoides hydrophyllum extract.

[0027] In the embodiments of the present application, the effective amount of the Nymphoides hydrophyllum composition is 100-250 mg / day for a 60-kg adult, and at least 200 mg / day is preferred. The effective amount may vary depending on the species, weight, and age of the individual, as long as the variation is within the range that can be calculated by those skilled in the art based on the prior art, or falls within the acceptable error range in the technical field, for example, an error value of ±10% of the true value. The present application covers such ranges, and does not fall outside the scope of protection because the values are not exactly the same.

[0028] In the embodiments of the present application, the individual refers to a mammal that has been exposed to heavy metals for a period of time or has accumulated a heavy metal content in the body tissue or organ that exceeds the medically acceptable range.

[0029] The heavy metals referred to in the present application include lead, arsenic, or other metal elements or their salts that are harmful to the human body.

[0030] Unless otherwise defined, the technical or scientific terms used in the present application are based on the meanings generally understood by those skilled in the art or the same meanings.

[0031] The term "extraction procedure" refers to a procedure that can separate a target substance or a segment containing the target substance from a mixture based on the different solubilities of the substances in the mixture, such as water extraction, alcohol extraction, supercritical extraction, etc.

[0032] The term "blanching" refers to the rapid change in temperature to retain the activity of active ingredients in Nymphoides hydrophyllum, including detoxification components and enzymes, so that they are not destroyed by environmental factors.

[0033] The term "composition" containing the extract of Gynura divaricata L. disclosed in the present application, and taking the extract of Gynura divaricata L. disclosed in the present application as the main active ingredient, can be prepared into different dosage forms according to the use object, use method, etc., and can be added with excipients, carriers or other pharmaceutically or food industry acceptable ingredients. For example, the composition is a medicine, a nutritional supplement, a food, a therapeutic preparation.

[0034] The term "effective amount" refers to the amount of the extract of Gynura divaricata L. that can achieve the alleviation of one or more symptoms of the disease being treated, the reduction of discomfort of one or more symptoms, or the slowing of the progression of the disease, and the effective amount will vary depending on the administration time, administration dosage form, administration object, etc. As long as the variation of the effective amount does not exceed the range that can be calculated by those skilled in the art in the technical field to which the present application belongs based on the prior art, or falls within the range of tolerable error in the technical field, for example, the error value is ±10% of the true value, it is within the scope of the claims of the present application, and does not fall out of the protection scope of the claims of the present application because the numerical values are not exactly the same. For example, when the administration object is an adult, the effective amount of the extract of Gynura divaricata L. disclosed in the present application per day is 100-250 mg / day, and the administration time is at least 14 days.

[0035] The term "treating" means reversing, alleviating, inhibiting the progression of, one or more symptoms of the condition or disease to which this term applies, or preventing the occurrence of the condition to which this term applies or its complications. The term "treatment" as used herein refers to the therapeutic act of "treating" as defined herein.

[0036] The term "administration" refers to the manner in which the extract of Gynura divaricata L. disclosed in the present application or the composition containing the extract of Gynura divaricata L. is provided to an individual, such as external use, oral administration.

[0037] The term "tolerable error" refers to the difference between the index value and the data or number provided by the present application, but the difference is scientifically acceptable, and there is no statistical difference or no substantial identity affecting the corresponding results between the data or number disclosed in the present application.

[0038] In addition, any figure disclosed in the specification of the present application is used as an illustration or explanation of the technical features and / or effects of the present application, and does not limit the protection scope of the claims of the present application; if the figure disclosed in the present application contains specific numerical values or numbers, the interpretation range should include the true value of the data and the tolerable error of those skilled in the art in the technical field to which the present application belongs.

[0039] The following is an explanation of the technical features and effects of the present application by taking a number of embodiments and accompanying drawings as examples.

[0040] Example 1: Preparation of the extract of Gynura divaricata L.

[0041] Fresh Nymphoides hydrophyllum leaves were subjected to blanching, crushing, extraction, filtration, centrifugation, hydration and lyophilization in sequence, wherein water and 95% alcohol were used as extraction solvents in the extraction procedure to obtain Nymphoides hydrophyllum water extract and Nymphoides hydrophyllum alcohol extract.

[0042] The Nymphoides hydrophyllum water extract and Nymphoides hydrophyllum alcohol extract were subjected to HPLC analysis, and the results are shown in Figure 1A and Figure 1B , wherein the HPLC conditions included: 98% methanol as solvent; 1.0 mL / min as flow rate; gradient elution as elution mode; 10 μL as injection volume; 60 minutes as stop time; 30°C as column temperature; and 210 nm as detection wavelength. From the results in Figure 1A and Figure 1B , it can be seen that the Nymphoides hydrophyllum water extract and Nymphoides hydrophyllum alcohol extract had a distinct wave front between 13.5-14.5 minutes of retention time. By comparing the HPLC pattern of the dLGG standard, it can be seen that the distinct wave front in the HPLC pattern of the Nymphoides hydrophyllum water extract and Nymphoides hydrophyllum alcohol extract was dLGG (1,2-di-O-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol), which means that the Nymphoides hydrophyllum water extract and Nymphoides hydrophyllum alcohol extract disclosed in the present application were rich in dLGG.

[0043] Example 2: Lead toxicity test

[0044] Six-week-old SD rats were fed with 1 mL of 2000 ppm lead acetate aqueous solution every day. Except for the blank group, the other two groups of rats were given 200 mg of Nymphoides hydrophyllum water extract sample or Nymphoides hydrophyllum alcohol extract sample equivalent to the adult intake amount every day during the feeding of the lead acetate aqueous solution, and the conversion standard was calculated according to the common knowledge in the art. After 14 days of the test, blood lead content and liver index analysis were performed by blood sampling, and the results are shown in Figure 3 , Figure 4 , Table 1 and Table 2.

[0045] Table 1: Blood lead concentration detection and analysis results of rats in each group

[0046]

[0047] Table 2: Liver index detection and analysis results of rats in each group

[0048]

[0049] From the results in Figure 3 and Figure 4The results show that the blood lead concentration and the contents of aspartate amino transferase (AST) and alanine amino transferase (ALT) of the blank group rats treated by high lead exposure for 14 days are significantly increased, which shows that the lead ions continuously administered to the individual cannot be metabolized by the individual and accumulated in the body, and cause liver function damage. When the rats are exposed to a high lead environment, the blood lead concentration of the rats administered with the aqueous extract of the A. verticillata sample or the alcoholic extract of the A. verticillata sample is reduced by 31.9% and 28.3% compared with the blank group rats, and the aspartate amino transferase is reduced by 23.3% and 41.4%, respectively. That is, the aqueous extract of the A. verticillata sample or the alcoholic extract of the A. verticillata sample can effectively reduce the lead concentration in the blood of the rats and improve the liver function index.

[0050] The results of this example prove that the A. verticillata extract disclosed in the present application indeed has the activity of removing heavy metals such as lead in the body, that is, by administering an effective amount of the A. verticillata extract disclosed in the present application or a composition containing the A. verticillata extract to an individual, the effects of treating or preventing lead poisoning, liver damage or liver disease caused by excessive exposure to heavy metals can be effectively achieved.

Claims

1. Use of an extract of Phyllanthus spp. in the manufacture of a medicament for the treatment of liver impairment caused by lead poisoning, characterized in that, The extract of the Gynura formosana is a galactolipid-rich mixture, the Gynura formosana is named as Crassocephalum rabens 1,2-di-O-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol; the extract of the Gynura formosana is obtained from the Gynura formosana through an extraction procedure, and the extraction solvent used in the extraction procedure is water or a lower alcohol, the lower alcohol is 95% ethanol.

2. Use according to claim 1, characterized in that, The lead poisoning is caused by exposure to lead or substances containing lead ions.

3. Use of an extract of Phyllanthus spp. in the manufacture of a medicament for lowering blood lead concentration, characterized in that, The extract of the Gynura formosana is a galactolipid-rich mixture, the Gynura formosana is named as Crassocephalum rabens 1,2-di-O-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol; the extract of the Gynura formosana is obtained from the Gynura formosana through an extraction procedure, and the extraction solvent used in the extraction procedure is water or a lower alcohol, the lower alcohol is 95% ethanol.

Images